Last year, the FDA approved three new antibody-drug conjugates for treating cancer.

Genitourinary Cancers Symposium reaches beyond the latest prostate, bladder and kidney cancer treatments.

Updated study results show antibody-drug conjugate plus Keytruda shrinks tumors in 73% of patients.

In a clinical trial, 46% of responding participants experienced a complete response lasting at least 12 months.

Novel antibody-drug conjugate shrank tumors in more than 40% of people previously treated with immunotherapy.

Here’s a list of the approved drugs to treat bladder cancer. Click on any of the medications for more info on indications, dosing and...

An anthrax-based treatment holds promise against this difficult-to-treat malignancy.